You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

59 Results
Guidelines and Advice
Status: Current
ID: GL 2-30a
Version: N/A
Mar 2020
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Jun 2025
Guidelines and Advice
Jan 2020
Guidelines and Advice
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-10
Version: 1
May 2021
Guidelines and Advice
Dec 2015
Guidelines and Advice
Guidelines and Advice
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Jun 2025

Pages